Cardiology Devices
•38 stocks
•
Total Market Cap: Loading...
Market Cap Distribution
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (38)
%
| Company | Market Cap | Price |
|---|---|---|
|
Cardiology devices and related therapies (e.g., Impella pumps, IVL) form a core MedTech growth area.
|
$458.89B |
$190.72
-0.67%
|
|
Abbott's growth is driven by cardiology devices such as Navitor TAVR, MitraClip/TriClip, and related structural heart technology.
|
$230.52B |
$132.57
-1.21%
|
|
Directly manufactures and markets cardiovascular medical devices, including WATCHMAN LAAC and AF ablation products (FARAPULSE).
|
$141.15B |
$95.41
-1.94%
|
|
Cardiology Devices - defibrillators, monitors, and related cardiac care equipment (e.g., LIFEPAK 35).
|
$139.34B |
$364.60
-1.54%
|
|
Medtronic's core Cardiology Devices portfolio includes leadless pacemakers, ablation catheters, and structural heart implants (e.g., TAVR), driving its largest revenue and growth in cardiovascular care.
|
$122.30B |
$95.45
-1.27%
|
|
Edwards Lifesciences' core offerings are cardiology devices, including transcatheter heart valves and other structural heart therapies.
|
$43.37B |
$73.94
-1.58%
|
|
Cardiology-related devices (e.g., cardiac imaging and interventional tools) are part of Philips' D&T suite.
|
$26.88B |
$27.35
|
|
Core product is a patch-based cardiac monitoring device (Cardiology Devices).
|
$5.63B |
$176.20
-1.06%
|
|
BIOTRONIK/Teleflex vascular-interventional assets (DCBs, drug-eluting stents, resorbable scaffold, covered stents) fall under Cardiology Devices and endovascular therapies.
|
$5.28B |
$119.42
-4.53%
|
|
Cardiology Devices encompass Merit's interventional cardiovascular products and lead-management capabilities.
|
$4.67B |
$78.99
-3.99%
|
|
Operates in cardiology devices markets such as electrophysiology and structural heart, via contract manufacturing.
|
$3.53B |
$101.05
-1.93%
|
|
Core cardiopulmonary hardware offerings (e.g., Essenz heart-lung machine and oxygenators) fall under cardiovascular device categories.
|
$2.76B |
$50.69
-2.14%
|
|
Produces cardiovascular-related devices like carotid shunts and occlusion catheters, aligning with Cardiology Devices.
|
$1.90B |
$86.56
+2.82%
|
|
AtriCure's AtriClip LAA exclusion devices (e.g., FLEX-Mini) represent a core cardiology device offering in left atrial appendage management.
|
$1.79B |
$36.18
-0.47%
|
|
Company's core revenue derives from cardiology devices (e.g., On-X heart valve, arch repair devices).
|
$1.72B |
$40.20
-1.18%
|
|
Cardiology ablation catheters and surgical AF devices (e.g., 360 Catheter, AF Clamp) are directly categorized as Cardiology Devices.
|
$1.22B |
$18.12
+2.66%
|
|
Core product category; wearable cardioverter defibrillators and related cardiology devices directly produced by Kestra.
|
$1.13B |
$22.00
-6.82%
|
|
Auryon, AlphaVac, AngioVac, and NanoKnife are direct medical devices used in cardiovascular/interventional procedures, aligning with Cardiology Devices.
|
$446.97M |
$11.00
-6.38%
|
|
Surmodics' vascular intervention devices (SurVeil DCB, Pounce thrombectomy, Sublime radial access) are direct Cardiology Devices.
|
$409.39M |
$28.63
-0.62%
|
|
Defibrillators are cardiology-focused medical devices sold by AHG.
|
$383.46M |
$1.60
-6.98%
|
|
Hardware device category in cardiology/vascular diagnostics, aligning with QuantaFlo’s cardiovascular testing use.
|
$340.79M |
$30.56
-2.55%
|
|
FUROSCIX targets cardiology patients (heart failure), aligning with the Cardiology Devices category.
|
$299.33M |
$5.67
|
|
The company sells proprietary cardiology/interventional devices (MAGiC, MAGiC Sweep, Map-iT, EMAGIN, etc.) directly to hospitals.
|
$264.02M |
$3.07
-9.17%
|
|
Core product line is the PURE EP Platform for intracardiac electrophysiology, fitting under cardiology devices.
|
$215.15M |
N/A
|
|
Barostim targets the cardiovascular/hearT failure market as a cardiology device, aligning with Cardiology Devices.
|
$210.41M |
$7.88
+0.51%
|
|
Direct product: DurAVR Transcatheter Heart Valve (TAVR) system in the structural heart/cardiology devices category.
|
$166.25M |
$4.61
-6.11%
|
|
AVIM therapy and Virtue SAB are cardiovascular medical devices developed by OBIO, thus Cardiology Devices.
|
$120.68M |
$3.15
+8.25%
|
|
InspireMD produces carotid stent systems (CGuard Prime) and neuroprotection devices (SwitchGuard NPS) used in CAS/TCAR, directly aligning with Cardiology Devices.
|
$73.22M |
$2.39
-0.90%
|
|
DrugSorb-ATR is a cardiology/perioperative device intended for use in cardiac surgery to reverse ticagrelor, aligning with Cardiology Devices.
|
$61.61M |
$0.98
-0.40%
|
|
Cardiology devices: portable 12-lead ECG synthesis device used for cardiac monitoring.
|
$55.78M |
$1.65
-6.78%
|
|
CV-focused products like ProxiCor and VasCure indicate cardiovascular/cardiology device offerings.
|
$36.18M |
$0.89
+1.02%
|
|
Direct cardiology ablation devices (vCLAS system) used for VT treatment.
|
$31.07M |
$2.02
-14.04%
|
|
Label expansions into cardiac surgery imply applicability in Cardiology Devices.
|
$11.78M |
$2.54
-5.58%
|
|
Proprietary cardiology devices, including Holter monitors and EECP systems, place Vaso in Cardiology Devices.
|
$7.48M |
$0.12
+2.27%
|
|
Cardiology devices: BioCardia's products are cardiac-focused delivery systems and cell therapies used in heart disease.
|
$7.04M |
$1.36
+0.37%
|
|
SeaStar's Selective Cytopheretic Device (SCD) is a hospital-imaging/monitoring-adjacent therapeutic device used in cardiac/critical care contexts, aligning with Cardiology Devices.
|
$6.04M |
$0.57
-4.73%
|
|
Core product category includes cardiology-specific devices like Bioflux, Biocore, and Biocore Pro.
|
$5.48M |
$0.59
-14.10%
|
|
Core EP-focused cardiac electrophysiology devices are the company's primary products (VIVO System and related EP tools).
|
$1.60M |
$2.76
-2.82%
|
Loading industry metrics...
Loading comparison data...
